Zealand Pharma A/S (CPH: ZEAL)

Denmark flag Denmark · Delayed Price · Currency is DKK
726.50
-1.50 (-0.21%)
Jan 30, 2025, 4:10 PM CET
52.56%
Market Cap 51.68B
Revenue (ttm) 76.87M
Net Income (ttm) -1.05B
Shares Out 70.65M
EPS (ttm) -16.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 91,516
Average Volume 165,044
Open 719.00
Previous Close 728.00
Day's Range 712.50 - 730.00
52-Week Range 431.00 - 972.00
Beta 0.54
RSI 48.51
Earnings Date Feb 20, 2025

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 253
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol ZEAL
Full Company Profile

Financial Performance

In 2023, Zealand Pharma's revenue was 342.79 million, an increase of 229.65% compared to the previous year's 103.99 million. Losses were -703.74 million, -41.46% less than in 2022.

Financial Statements

News

Zealand CEO on navigating the obesity space among the two biggest players

CNBC's Angelica Peebles talks to Zealand Pharma CEO Adam Steensberg about how he's differentiating Zealand in the obesity drug race.

15 days ago - CNBC

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhage...

17 days ago - GlobeNewsWire

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Press Release – No. 2 / 2025 Steven R.

23 days ago - GlobeNewsWire

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Press Release – No. 1 / 2025 Zealand Pharma to present at the 43rd Annual J.P.

24 days ago - GlobeNewsWire

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 53 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...

5 weeks ago - GlobeNewsWire

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024  – Zealand Pharma A/S (“Zealand”) (Nasdaq: Z...

5 weeks ago - GlobeNewsWire

Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide

The CEO of Danish drugmaker Zealand Pharma said on Friday that data posted by Novo Nordisk's late-stage study of its next-generation obesity drug CagriSema supported Zealand's own monotherapy approach...

5 weeks ago - Reuters

FDA drug rejection hits Zealand Pharma shares

Treatment for short bowel syndrome fails to win approval from US regulator

5 weeks ago - Financial Times

US FDA declines to approve Zealand Pharma's bowel disease drug

The U.S. Food and Drug Administration declined to approve Zealand Pharma's bowel disease drug, the company said on Thursday.

6 weeks ago - Reuters

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concl...

6 weeks ago - GlobeNewsWire

Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintide

Danish biotechnology company Zealand Pharma said on Tuesday it had enrolled the first patient in its so-called Phase 2b ZUPREME-1 trial with its obesity treatment candidate petrelintide.

7 weeks ago - Reuters

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the fir...

7 weeks ago - GlobeNewsWire

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr....

2 months ago - Market Watch

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no.

2 months ago - GlobeNewsWire

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...

2 months ago - GlobeNewsWire

Zealand Pharma Gains as JPMorgan Flags $10 Billion Opportunity

Zealand Pharma A/S briefly reclaimed its position as this year’s best performer in the Stoxx 600 Health Care Index on Friday, after analysts at JPMorgan Chase & Co. predicted the Danish biotech firm’s...

2 months ago - BNN Bloomberg

Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4

Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.

3 months ago - Reuters

Zealand’s Weight-Loss Drug Has Minimal Side Effects in Study

Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than some other next-generation contenders in the growing market for obesity dr...

3 months ago - BNN Bloomberg

Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/...

3 months ago - GlobeNewsWire

Zealand Pharma seeks partner for its 'next generation' weight loss drug

CNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global partner.

3 months ago - CNBC International TV

Zealand Pharma targeting 'next generation' of obesity drugs, CEO says

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover speculation.

3 months ago - CNBC International TV

Can this European biotech challenge Eli Lilly in the booming weight-loss market?

GLP-1s have dominated discussions in 2024 among those exploring weight-loss treatments. However, Zealand Pharma A/S (CPH: ZEAL), a Danish biotechnology firm, is already developing what it calls the “n...

3 months ago - Invezz